Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)

Conference Reports for NATAP

The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA


Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB)

	AASLD 2024 Nov 15-19 San Diego Grace Lai Hung Wong,1 Man-Fung Yuen,2 Patrick Kennedy,3 Ashley Brown,4 Chi-Yi Chen,5 Gin-Ho Lo,6 Pei-Yuan Su,7 Sheng-Shun Yang,8 Kosh Agarwal,9 Deana Antoniello,10 Elina Medvedeva,10 Emily P. Thi,10 Christine Espiritu,10 Christina Iott,10 Ingrid Graves,10 Sharie C. Ganchua,10 Sanjana Kangabam,10 Timothy Eley,10 Tom Evans,11 Bethan Jones,11 Leon Hooftman,11 Mark Anderson,12 Tiffany Fortney,12 Gavin Cloherty,12 Gaston Picchio,10 Karen Sims,10 Tilly Varughese10